Lexaria Bioscience Corp. (LEXX) closed at $2.82 on October 21, 2026, up 6.4% from the previous close, on volume of 28,297 shares (30-day average 86,133).
Data as of October 21, 2026.
Lexaria's Human Study GLP-1-H26-7 Reaches Full Enrollment and Continues Dosing on Schedule
ACCESS Newswire (Wed, 21-Oct 9:25 AM ET)
Lexaria Announces Results from Animal Study GLP-1-A26-1
ACCESS Newswire (Thu, 15-Oct 9:10 AM ET)
Lexaria Highlights an $89 Billion Oral GLP-1 Opportunity as Novo Signals a Shift From Injections
Market Chameleon (Wed, 7-Oct 6:53 AM ET)
GLP-1 Weight-Loss/Diabetes Industries Continue Transition to Oral Medications
ACCESS Newswire (Tue, 6-Oct 9:10 AM ET)
Lexaria Highlights $4.60 Per Share Cash on Hand After $7.9 Million Capital Boost
Market Chameleon (Fri, 18-Sep 5:57 AM ET)
Lexaria Updates Financial Position
ACCESS Newswire (Thu, 17-Sep 9:10 AM ET)
Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds
ACCESS Newswire (Wed, 9-Sep 4:15 PM ET)
Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds
ACCESS Newswire (Tue, 8-Sep 8:05 AM ET)
Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference
ACCESS Newswire (Fri, 4-Sep 9:20 AM ET)
Lexaria Receives USD$2.6 Million Tax Rebate Payment
ACCESS Newswire (Tue, 1-Sep 9:15 AM ET)
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
Lexaria Bioscience Corp. trades on the NASDAQ stock market under the symbol LEXX.
As of October 21, 2026, LEXX stock price climbed to $2.82 with 28,297 million shares trading.
LEXX has a beta of 1.22, meaning it tends to be more sensitive to market movements. LEXX has a correlation of 0.01 to the broad based SPY ETF.
LEXX has a market cap of $5.94 million. This is considered a Sub-Micro Cap stock.
Last quarter Lexaria Bioscience Corp. reported $0 in Revenue and -$1.20 earnings per share. This fell short of revenue expectation by $-20,000 and missed earnings estimates by -$.30.
In the last 3 years, LEXX traded as high as $102.75 and as low as $2.43.
The top ETF exchange traded funds that LEXX belongs to (by Net Assets): VXF.
LEXX has underperformed the market in the last year with a price return of -80.1% while the SPY ETF gained +16.3%. LEXX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -68.7% and -13.0%, respectively, while the SPY returned +4.4% and -0.8%, respectively.
LEXX support price is $2.38 and resistance is $2.92 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LEXX shares will trade within this expected range on the day.
